ESCMID Global 2026: Shionogi presents new real-world data highlighting clinical effectiveness of Fetroja®/Fetcroja® (cefiderocol) in MBL-producing Enterobacterales infections
・Real world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 8...
Publisher
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
・Real world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 8...
Source route
Continue on shionogi.com
Leave the platform to read the original full article on the publisher site.
Source: Shionogi
Scope: Industry
Related coverage
More related coverage
Research & Development
At Zoetis, we're driven by science and purpose. See how we use the most innovative research and tech...
ask our experts monoclonal antibodies explained
Watch our experts answer some common questions we’ve received from veterinarians about monoclonal an...